Airway Fusobacterium is Associated with Poor Response to Immunotherapy in Lung Cancer

References

• Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112:1421–1427. doi:10.1038/bjc.2015.124
   PubMed Web of Science ®Google Scholar
• Otoshi T, Nagano T, Tachihara M, Nishimura Y. Possible biomarkers for cancer immunotherapy. Cancers. 2019;11. doi:10.3390/cancers11070935
   PubMed Web of Science ®Google Scholar
• Cao M, Chen W. Epidemiology of lung cancer in China. Thorac Cancer. 2019;10:3–7. doi:10.1111/1759-7714.12916
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2–12. doi:10.3978/j.issn.1000-9604.2015.01.06
   PubMed Web of Science ®Google Scholar
• She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143:1117–1126. doi:10.1378/chest.11-2948
   PubMed Web of Science ®Google Scholar
• Dickson RP. The microbiome and critical illness. Lancet Respir Med. 2016;4:59–72. doi:10.1016/S2213-2600(15)00427-0
   PubMed Web of Science ®Google Scholar
• Faner R, Sibila O, Agusti A, et al. The microbiome in respiratory medicine: current challenges and future perspectives. Eur Respir J. 2017:49. doi:10.1183/13993003.02086-2016
   Web of Science ®Google Scholar
• Shukla SD, Budden KF, Neal R, Hansbro PM. Microbiome effects on immunity, health and disease in the lung. Clin Transl Immunol. 2017;6:e133. doi:10.1038/cti.2017.6
   PubMed Web of Science ®Google Scholar
• Peters BA, Hayes RB, Goparaju C, Reid C, Pass HI, Ahn J. The microbiome in lung cancer tissue and recurrence-free survival. Cancer Epidemiol Biomarkers Prev. 2019;28:731–740. doi:10.1158/1055-9965.EPI-18-0966
   PubMed Web of Science ®Google Scholar
• Song L, Ma S, Chen L, Miao L, Tao M, Liu H. Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer. Cancer Sci. 2019;110:2100–2109. doi:10.1111/cas.14068
   PubMed Web of Science ®Google Scholar
• Tsay JJ, Wu BG, Badri MH, et al. Airway microbiota is associated with upregulation of the pi3k pathway in lung cancer. Am J Respir Crit Care Med. 2018;198:1188–1198. doi:10.1164/rccm.201710-2118OC
   PubMed Web of Science ®Google Scholar
• Jin C, Lagoudas GK, Zhao C, et al. Commensal microbiota promote lung cancer development via γδ T cells. Cell. 2019;176:998–1013 e16. doi:10.1016/j.cell.2018.12.040
   PubMed Web of Science ®Google Scholar
• Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437–1444. doi:10.1093/annonc/mdy103
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97. doi:10.1126/science.aan3706
   PubMed Web of Science ®Google Scholar
• Liu T, Xiong Q, Li L, Hu Y. Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea. Immunotherapy. 2019;11:385–396. doi:10.2217/imt-2018-0144
   PubMed Web of Science ®Google Scholar
• Perrone F, Belluomini L, Mazzotta M, et al. Exploring the role of respiratory microbiome in lung cancer: a systematic review. Crit Rev Oncol Hematol. 2021;164:103404. doi:10.1016/j.critrevonc.2021.103404
   PubMed Web of Science ®Google Scholar
• Doring G, Parameswaran IG, Murphy TF. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol Rev. 2011;35:124–146. doi:10.1111/j.1574-6976.2010.00237.x
   PubMed Web of Science ®Google Scholar
• Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5:e8578. doi:10.1371/journal.pone.0008578
   PubMed Web of Science ®Google Scholar
• McCoy AN, Araujo-Perez F, Azcarate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. PLoS One. 2013;8:e53653. doi:10.1371/journal.pone.0053653
   PubMed Web of Science ®Google Scholar
• Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res. 2012;160:258–266. doi:10.1016/j.trsl.2012.02.005
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103. doi:10.1126/science.aan4236
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–108. doi:10.1126/science.aao3290
   PubMed Web of Science ®Google Scholar
• Frankel AE, Coughlin LA, Kim J, et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 2017;19:848–855. doi:10.1016/j.neo.2017.08.004
   PubMed Web of Science ®Google Scholar
• Sano T, Huang W, Hall JA, et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell. 2015;163:381–393. doi:10.1016/j.cell.2015.08.061
   PubMed Web of Science ®Google Scholar
• Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019;17:156–166. doi:10.1038/s41579-018-0129-6
   PubMed Web of Science ®Google Scholar
• Han YW. Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol. 2015;23:141–147. doi:10.1016/j.mib.2014.11.013
   PubMed Web of Science ®Google Scholar
• Kaplan A, Kaplan CW, He X, McHardy I, Shi W, Lux R. Characterization of aid1, a novel gene involved in Fusobacterium nucleatum interspecies interactions. Microb Ecol. 2014;68:379–387. doi:10.1007/s00248-014-0400-y
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195–206. doi:10.1016/j.chom.2013.07.012
   PubMed Web of Science ®Google Scholar
• Shokeen B, Park J, Duong E, et al. Role of FAD-I in fusobacterial interspecies interaction and biofilm formation. Microorganisms. 2020;8:70. doi:10.3390/microorganisms8010070
   PubMed Web of Science ®Google Scholar
• Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358:1443–1448. doi:10.1126/science.aal5240
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65:1973–1980. doi:10.1136/gutjnl-2015-310101
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170:548–63 e16. doi:10.1016/j.cell.2017.07.008
   PubMed Web of Science ®Google Scholar
• Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42:344–355. doi:10.1016/j.immuni.2015.01.010
   PubMed Web of Science ®Google Scholar
• Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276:112–120. doi:10.1111/imr.12518
   PubMed Web of Science ®Google Scholar
• Sanders BE, Umana A, Lemkul JA, Slade DJ. FusoPortal: an interactive repository of hybrid MinION-sequenced fusobacterium genomes improves gene identification and characterization. mSphere. 2018;3. doi:10.1128/mSphere.00228-18
   Web of Science ®Google Scholar